Treatment with IL-33 up-regulated proteins expression of IL-4 (Figure 5d), IL-5 (Figure 5e, and IL-13 (Figure 5f), and down-regulated IFN-γ mRNA expression (a Th1 marker, Figure 5h) in livers, indicating that IL-33 treatment induced a switch from a Th1 to a Th2 immunological profile in the livers of two experimental models of NASH. Here, IL33 is linked to metabolic dysfunction-associated steatohepatitis.